6:23 PM
 | 
Jul 25, 2013
 |  BC Extra  |  Top Story

Tecfidera sales trounce estimates

Biogen Idec Inc. (NASDAQ:BIIB) reported $192.1 million in 2Q13 sales of newly launched multiple sclerosis drug Tecfidera dimethyl fumarate, more than double Street estimates of around $75 million. The company, which launched Tecfidera in the U.S. in April, attributed $110 million of sales to patient demand and $82 million to inventory building. On a conference call to...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >